• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Bristol-Myers Squibb Co (BMY)

Common Stock
Sell: $57.64|Buy: $57.96|Change: 0.63 (-1.08%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Address

Route 206 and Province Line Road
Princeton
New Jersey
NJ
USA
08543

Telephone

+1 609 252-4621

Website

https://www.bms.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Bristol-Myers Squibb Co Annual Report for 20262027-02-11T00:00:00
Bristol-Myers Squibb Co Fourth Quarter Earnings Conference Call for 20262027-02-05T08:00:00
Bristol-Myers Squibb Co Fourth Quarter Earnings Result for 20262027-02-05T00:00:00
Bristol-Myers Squibb Co Third Quarter Earnings Conference Call for 20262026-10-29T08:00:00
Bristol-Myers Squibb Co Third Quarter Earnings Results for 20262026-10-29T00:00:00
Bristol-Myers Squibb Co Second Quarter Earnings Conference Call for 20262026-07-30T08:00:00
Bristol-Myers Squibb Co Second Quarter Earnings Result for 20262026-07-30T00:00:00
Bristol-Myers Squibb Co Annual General Meeting for 20262026-05-06T10:00:00
Bristol-Myers Squibb Co First Quarter Earnings Conference Call for 20262026-04-30T08:00:00
Bristol-Myers Squibb Co First Quarter Earnings Results for 20262026-04-30T00:00:00
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference2026-03-02T09:50:00

Previous key dates

NameKey Date
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference2026-03-02T09:50:00
Bristol-Myers Squibb Co Annual Report for 20252026-02-11T00:00:00
Bristol-Myers Squibb Co Fourth Quarter Earnings Conference Call for 20252026-02-05T08:00:00
Bristol-Myers Squibb Co Fourth Quarter Earnings Result for 20252026-02-05T00:00:00
J.P. Morgan’s 44th Annual Healthcare Conference2026-01-12T10:30:00
Hematology-Focused Investor Event2025-12-11T09:00:00
Citi’s 2025 Global Healthcare Conference2025-12-04T09:00:00
Bristol-Myers Squibb Co Third Quarter Earnings Conference Call for 20252025-10-30T08:00:00
Bristol-Myers Squibb Co Third Quarter Earnings Results for 20252025-10-30T00:00:00
Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum2025-09-23T09:40:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-08T08:30:00
Bristol-Myers Squibb Co Second Quarter Earnings Conference Call for 20252025-07-31T08:00:00
Bristol-Myers Squibb Co Second Quarter Earnings Results for 20252025-07-31T00:00:00
Goldman Sachs 46th Annual Global Healthcare Conference2025-06-11T10:00:00
Bernstein 41st Annual Strategic Decisions Conference2025-05-28T15:30:00
Bristol-Myers Squibb Co Annual General Meeting for 20252025-05-06T10:00:00
Bristol-Myers Squibb Co First Quarter Earnings Conference Call for 20252025-04-24T08:00:00
Bristol-Myers Squibb Co First Quarter Earnings Results for 20252025-04-24T00:00:00
Leerink Partners 2025 Global Healthcare Conference2025-03-12T11:20:00
TD Cowen 45th Annual Health Care Conference2025-03-04T14:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.